Cargando…

The hidden burden of adult allergic rhinitis: UK healthcare resource utilisation survey

BACKGROUND: The affliction of allergic rhinitis (AR) has been trivialised in the past. Recent initiatives by the European Academy of Allergy & Clinical Immunology and by the EU parliament seek to rectify that situation. The aim of this study was to provide a comprehensive picture of the burden a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Price, David, Scadding, Glenis, Ryan, Dermot, Bachert, Claus, Canonica, G. Walter, Mullol, Joaquim, Klimek, Ludger, Pitman, Richard, Acaster, Sarah, Murray, Ruth, Bousquet, Jean
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4650835/ https://www.ncbi.nlm.nih.gov/pubmed/26583068 http://dx.doi.org/10.1186/s13601-015-0083-6

Ejemplares similares

A common language to assess allergic rhinitis control: results from a survey conducted during EAACI 2013 Congress
por: Hellings, Peter W., et al.
Publicado: (2015)

Management of persistent allergic rhinitis: evidence-based treatment with levocetirizine
por: Mullol, Joaquim, et al.
Publicado: (2005)

P07 - Treatment load in the therapy management of allergic rhinitis: a UK retrospective database study
por: Carter, Victoria, et al.
Publicado: (2014)

Allergic rhinitis and asthma symptoms in a real-life study of MP-AzeFlu to treat multimorbid allergic rhinitis and asthma
por: Price, David, et al.
Publicado: (2020)

Short and long-term safety of MP29-02*: a new therapy for the treatment of allergic rhinitis
por: Price, David, et al.
Publicado: (2013)

A new therapy (MP29-02*) effectively targets the entire seasonal allergic rhinitis symptom complex
por: Price, David, et al.
Publicado: (2013)

UK prescribing practices as proxy markers of unmet need in allergic rhinitis: a retrospective observational study
por: Price, David B, et al.
Publicado: (2016)

A new therapy (MP29-02*) effectively controls nasal symptoms of seasonal allergic rhinitis irrespective of severity
por: Scadding, Glenis, et al.
Publicado: (2013)

A new therapy (MP29-02*) provides effective relief from all individual nasal and ocular symptoms of seasonal allergic rhinitis
por: Hellings, Peter, et al.
Publicado: (2013)

MP-AzeFlu Improves the Quality-of-Life of Patients with Allergic Rhinitis
por: van Weissenbruch, Ranny, et al.
Publicado: (2020)

A new efficacy parameter (complete/near complete symptom relief) in allergic rhinitis management: results with a new therapy MP29-02*
por: Bousquet, Jean, et al.
Publicado: (2013)

Higher efficacy of rupatadine 20 mg and 10 mg versus placebo in patients with perennial allergic rhinitis: a pooled responder analysis
por: Valero, Antonio, et al.
Publicado: (2020)

A new therapy (MP29-02*) effectively treats patients with seasonal allergic rhinitis who suffer most from the bothersome nasal symptom of congestion
por: Bachert, Claus, et al.
Publicado: (2013)

Evaluating the real-life effect of MP-AzeFlu on asthma outcomes in patients with allergic rhinitis and asthma in UK primary care
por: De Jong, Hilda J.I., et al.
Publicado: (2020)

Optimal management of allergic rhinitis
por: Scadding, Glenis K
Publicado: (2015)

MP29-02*’s advanced delivery system contributes to its efficacy in patients with moderate/severe seasonal allergic rhinitis
por: Scadding, Glenis, et al.
Publicado: (2015)

A new allergic rhinitis therapy (MP29-02*) provides nasal and ocular symptom relief days faster than current firstline monotherapies
por: Hellings, Peter, et al.
Publicado: (2015)

A new intranasal therapy (MP29-02*) is more effective than current firstline therapy regardless of season, symptom or severity.
por: Bachert, Claus, et al.
Publicado: (2015)

Clinically relevant effect of rupatadine 20 mg and 10 mg in seasonal allergic rhinitis: a pooled responder analysis
por: Mullol, Joaquim, et al.
Publicado: (2019)

Seasonal allergic rhinitis: fluticasone propionate and fluticasone furoate therapy evaluated
por: Kariyawasam, Harsha H, et al.
Publicado: (2010)

EUFOREA Comment on a Misleading Allergic Rhinitis Report [Letter]
por: Scadding, Glenis K, et al.
Publicado: (2023)

Rhinitis and Sinusitis
por: Scadding, Glenis K.
Publicado: (2008)

Patient Perceptions of Allergic Rhinitis and Quality of Life: Findings From a Survey Conducted in Europe and the United States
por: Canonica, G Walter, et al.
Publicado: (2008)

A new allergic rhinitis therapy (MP29-02*) provides effective and rapid symptom relief for patients who suffer most from the bothersome symptoms of nasal congestion or ocular itch
por: Fokkens, Wytske, et al.
Publicado: (2015)

Identification of gaps in the current allergic rhinitis guidelines and how these can be filled
por: Bousquet, Jean, et al.
Publicado: (2015)

Assessment of disease control in allergic rhinitis
por: Demoly, Pascal, et al.
Publicado: (2013)

Using magnetic resonance imaging to quantify the inflammatory response following allergen challenge in allergic rhinitis
por: Leaker, Brian R., et al.
Publicado: (2015)

A double-blind, placebo-controlled trial of the efficacy and safety of two doses of azelastine hydrochloride in perennial allergic rhinitis
por: Bousquet, Jean, et al.
Publicado: (2023)

Upper Airway Disease: Rhinitis and Rhinosinusitis
por: Scadding, Glenis K., et al.
Publicado: (2012)

Allergic respiratory disease care in the COVID-19 era: A EUFOREA statement
por: Scadding, Glenis K., et al.
Publicado: (2020)

Rapid onset of action and reduced nasal hyperreactivity: new targets in allergic rhinitis management
por: Bachert, C., et al.
Publicado: (2018)

Rhinitis, sinusitis and ocular disease – 2091. The MSYPQ: repeatability and applicability to rhinitis/rhinosinusitis
por: Sami, Amtul Salam, et al.
Publicado: (2013)

The need for patient-focused therapy for children and teenagers with allergic rhinitis: a case-based review of current European practice
por: Santos, Alexandra F, et al.
Publicado: (2015)

Allergic Rhinitis in Childhood and the New EUFOREA Algorithm
por: Scadding, Glenis Kathleen, et al.
Publicado: (2021)

Nasal IgE in subjects with allergic and non-allergic rhinitis
por: Eckrich, Jonas, et al.
Publicado: (2020)

Identifying the hidden burden of allergic rhinitis (AR) in community pharmacy: a global phenomenon
por: Tan, Rachel, et al.
Publicado: (2017)

ARIA guideline 2019: treatment of allergic rhinitis in the German health system
por: Klimek, Ludger, et al.
Publicado: (2019)

Benefits and harm of systemic steroids for short- and long-term use in rhinitis and rhinosinusitis: an EAACI position paper
por: Hox, Valerie, et al.
Publicado: (2020)

Correction to: Benefits and harm of systemic steroids for short- and long-term use in rhinitis and rhinosinusitis: an EAACI position paper
por: Hox, Valerie, et al.
Publicado: (2020)

Management of allergic rhinitis symptoms in the pharmacy Pocket guide 2022
por: Lourenço, Olga, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_8j93nbc10kiv5jgvkc2la1k8ke